跳至主要内容
临床试验/NCT01335373
NCT01335373已完成不适用

Observational Program Neo-Penotran® Forte

Bayer0 个研究点目标入组 13,024 人开始时间: 2010年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
Bayer
入组人数
13,024
主要终点
Percent rate of different vaginal infections

研究概览

简要总结

Vaginitis is the most common gynecologic diagnosis in the primary care setting. In approximately 90 percent of affected women, this condition occurs secondary to bacterial vaginosis, vulvovaginal candidiasis, trichomoniasis or mixed infection.

Neo-Penotran Forte is registered for treatment of these most common vaginal infections. Efficacy and safety of this product is already established, and this observational study was designed to learn more about practical use of Neo-Penotran® Forte in real life setting.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Patients older than 18 years with previously taken decision of their gynecologist to prescribe Neo-Penotran Forte according to registered indications, and microbiological tests were performed.

排除标准

  • Presence of contraindications according to package insert.

研究组 & 干预措施

Group 1

干预措施: Metronidazole/Miconazole (Neo-Penotran Forte, BAY86-5276) (Drug)

结局指标

主要结局

Percent rate of different vaginal infections

时间窗: Approximately within 6 months after the last patient last visit.

次要结局

  • Clinical characteristics of vaginitis after treatment.(Depending on treatment time chosen by the physician, after 7 or 14 days.)
  • Change of microbiological characteristics after treatment(Depending on treatment time chosen by the physician, after 7 or 14 days.)
  • Patient rating of tolerability and treatment results(Depending on treatment time chosen by the physician, after 7 or 14 days.)
  • Physician's rating of tolerability and treatment results(Depending on treatment time chosen by the physician, after 7 or 14 days.)

研究者

发起方
Bayer
申办方类型
Industry
责任方
Sponsor

相似试验